Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Nivolumab in R/R DLBCL and PMBCL
NCT03484819Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by National Cancer Institute. Started Dec 2019; status: completed.
02
Drugs
copanlisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT03484819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03484819.